Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
None (3) ·
Alprazolam (1) ·
Bromazepam (1) ·
Chlordiazepoxide (1) ·
Clobazam (1) ·
Clonazolam (1) ·
Clorazepate (1) ·
Diclazepam (1) ·
Estazolam (1) ·
Flualprazolam (1) ·
Flubromazepam (1) ·
Flubromazolam (1) ·
Flunitrazepam (1) ·
Flunitrazolam (1) ·
Flurazepam (1) ·
Lormetazepam (1) ·
Midazolam (1) ·
Nifoxipam (1) ·
Nitrazepam (1) ·
Oxazepam (1) ·
Pyrazolam (1) ·
Quazepam (1) ·
Temazepam (1) ·
Triazolam (1)
brand:
None (9) ·
Caplyta (1) ·
Dalmane (1) ·
Doral (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Onfi (1) ·
ProSom (1) ·
Restoril (1) ·
Rexulti (1) ·
Rohypnol (1) ·
Serax (1) ·
Tranxene (1) ·
Versed (1) ·
Vraylar (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1)
uses:
None (22) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (22) ·
0.25 mg (1) ·
42 mg PO once daily with food (no titration) (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
legal:
Showing below up to 26 results in range #1 to #26.